<DOC>
	<DOC>NCT01197287</DOC>
	<brief_summary>There are three elements to this study: - Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. - Part B: Single dose escalation in patients with mild/moderate COPD. 3 dose levels of QAK423 are planned in COPD patients. - Part C: Titrated repeat dosing for a maximum of 14 days in mild/moderate COPD patients. Repeat dosing is planned in COPD patients.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Part A: Healthy, male subjects aged 1855 years of age able to provide written informed consent prior to study participation and determined as in good health by past medical history, physical examination, ECG, laboratory tests and urinalysis. Parts B and C: Male or female (post menopausal or surgically sterilized) patients with COPD, aged 4075 years, with a smoking history of at least 10 pack years (i.e. smokers or exsmokers). Diagnosis of mild or moderate COPD, according to the GOLD guidelines. Postbronchodilator FEV1 at screening 5080% of predicted. No COPD exacerbations within the 3 months prior to dosing, no concomitant lung disease such as asthma, requirement for long term oxygen treatment or history of lung reduction surgery. No medical conditions that may jeopardize the subjects participation in the study Weigh less than 100 kg Use of any prescription drug or overthecounter (OTC) medication within 2 weeks prior to dosing. History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated). Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. History of clinically significant drug allergy. A known hypersensitivity to the study drug or drugs similar to the study drug. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
</DOC>